IntroductionMedical treatment of endometriosis ranges from symptomatic control to therapies aimed at suppressing the ovarian production of estrogen. Almost all the treatment strategies are suppressive rather than curative so that the discontinuation of therapy leads to recurrence of symptoms. In 2009 a systematic review of literature estimated the recurrence rate of endometriosis to be 21.5% and 40-50% within two and five years, respectively(1), which is much more prevalent than previously believed. Regrowth of residual lesions and de novo lesion formation are possible pathogenesis mechanisms leading to the recurrence of endometrial lesions. Radical surgery means the elimination of all possible endometriosis implants detected in pelvic and abdominal cavity, that is sometimes insufficient to radically remove these lesions; therefore, lesions often reappear postoperatively. Medical treatment options such as the application of gonadotropin-releasing hormone agonist (GnRH-a) plays an essential role in the management of endometriosis by reducing estrogen levels in order to promote the progressive atrophy of an ectopic endometrium(2).Our objective was to introduce a less invasive and low risk management strategy to prevent the recurrence of endometriosis through combination therapy. In this novel management approach, GnRH-a pre-treatment is used to reduce inflammations as well as endometriosis attachments, after diagnosis and staging of endometriosis through laparascopy.